A drug called RASBURICASE Injection is used to treat tumour lysis syndrome, which can happen during cancer treatment when a lot of cancer cells degrade and release a lot of uric acid into the circulation. Kidney damage and other severe problems may result from this. By converting uric acid into a more soluble form, RASBURICASE prevents its buildup and lowers the risk of renal and electrolyte abnormalities. Usually, the injection is given intravenously. It is most frequently used in patients with hematologic malignancies who are at a high risk of experiencing tumour lysis syndrome. To minimise any side effects and make sure the medication is effective in preventing or treating tumour lysis syndrome, regular monitoring is crucial throughout the course of the treatment.